

# Discussion Paper-Options for Possible Changes to the *Patented Medicines Regulations, 1994* and the Excessive Price Guidelines

The Board is committed to working with its stakeholders to resolve the issues discussed during the ongoing review of the Excessive Price Guidelines (Guidelines), as well as those arising from the Federal Court of Canada decision in *LEO Pharma*. In keeping with this commitment, the Board has just released a document for public consultation entitled: the Excessive Price – Options for Possible Changes to the *Patented Medicines Regulations, 1994* and the Excessive Price Guidelines.

The purpose of the discussion paper is to seek written feedback from all stakeholders on both proposed changes to the Guidelines stemming from the Board's ongoing review, as well as on a range of options to address the issues arising from the Federal Court decision.

Written comments should be sent to Ms. Sylvie Dupont, Secretary of the Board, no later than March 3, 2008, at [sdupont@pmprb-cepmb.gc.ca](mailto:sdupont@pmprb-cepmb.gc.ca), or by mail at PMPRB, Box L40, Standard Life Centre, 333 Laurier Avenue West, Suite 1400, Ottawa, Ontario, K1P 1C1.

Your feedback is important in this process. It will help guide the Board's eventual decision-making on the proposed changes and options. All comments will be considered in the Board's deliberations, with decisions expected on the various proposals and options in the Spring of 2008.

As with previous consultations, all submissions received by the Board will be posted on our Web site as part of the PMPRB's commitment to openness and transparency. ■

All stakeholders are welcome to provide comments on the Discussion Paper, which can be found on the Board's Web site under Consultations.